Franck Priou

3.0k total citations · 1 hit paper
25 papers, 760 citations indexed

About

Franck Priou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Franck Priou has authored 25 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Franck Priou's work include Cancer Treatment and Pharmacology (9 papers), Prostate Cancer Treatment and Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Franck Priou is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Prostate Cancer Treatment and Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Franck Priou collaborates with scholars based in France, Belgium and Spain. Franck Priou's co-authors include Frédéric Rolland, Stéphane Oudard, Stéphane Culine, Gwénaëlle Gravis, Loı̈c Mourey, Laurence Albigès, Florence Joly, Karim Fizazi, Christine Théodore and Brigitte Laguerre and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Franck Priou

25 papers receiving 744 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, Jean‐Marie Boher et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Franck Priou France	10	624	246	239	188	157	25	760
Joanna Vergidis Canada	12	772 1.2×	334 1.4×	386 1.6×	215 1.1×	201 1.3×	27	980
Zafeiris Zafeiriou United Kingdom	13	536 0.9×	422 1.7×	345 1.4×	158 0.8×	172 1.1×	31	873
Antonello Veccia Italy	16	523 0.8×	346 1.4×	176 0.7×	84 0.4×	198 1.3×	66	739
Davide Bimbatti Italy	13	398 0.6×	205 0.8×	158 0.7×	173 0.9×	75 0.5×	56	560
Kris Deprince United States	7	948 1.5×	252 1.0×	312 1.3×	168 0.9×	333 2.1×	15	1.2k
Daniel Khalaf Canada	12	1.1k 1.7×	411 1.7×	590 2.5×	300 1.6×	234 1.5×	41	1.2k
F. Gómez-Veiga Spain	14	707 1.1×	159 0.6×	196 0.8×	113 0.6×	155 1.0×	81	899
Satoshi Fukasawa Japan	17	709 1.1×	339 1.4×	122 0.5×	183 1.0×	144 0.9×	61	929
S. Polyakov Belarus	8	811 1.3×	180 0.7×	281 1.2×	142 0.8×	273 1.7×	20	940
Krista Noonan Canada	11	572 0.9×	191 0.8×	196 0.8×	73 0.4×	275 1.8×	31	704

Countries citing papers authored by Franck Priou

Since Specialization

Citations

This map shows the geographic impact of Franck Priou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Priou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Priou more than expected).

Fields of papers citing papers by Franck Priou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Priou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Priou. The network helps show where Franck Priou may publish in the future.

Co-authorship network of co-authors of Franck Priou

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Priou. A scholar is included among the top collaborators of Franck Priou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Priou. Franck Priou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lefeuvre‐Plesse, Claudia, Carole Hélissey, Franck Priou, et al.. (2021). 1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study. Annals of Oncology. 32. S1178–S1178. 2 indexed citations

Chatzipli, Aikaterini, Hervé Bonnefoi, Gaëtan MacGrogan, et al.. (2021). Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. British Journal of Cancer. 125(10). 1356–1364. 2 indexed citations

Colombo, Nicoletta, Justine Gantzer, Beyhan Ataseven, et al.. (2020). 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Annals of Oncology. 31. S614–S614. 2 indexed citations

Aldea, Mihaela, Gwénaëlle Gravis, Aude Fléchon, et al.. (2020). 614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects. Annals of Oncology. 31. S510–S510. 2 indexed citations

Auclin, Édouard, Philippe Barthélémy, Petri Bono, et al.. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer. 108. 33–40. 95 indexed citations

Dalban, Cécile, Marine Gross‐Goupil, Brigitte Laguerre, et al.. (2019). Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma. Annals of Oncology. 30. v391–v391. 3 indexed citations

Lavaud, Pernelle, Gwénaëlle Gravis, Florence Joly, et al.. (2016). Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.. Journal of Clinical Oncology. 34(15_suppl). 5080–5080. 4 indexed citations

Falandry, Claire, Wadih Rhondali, Gilles Freyer, et al.. (2015). Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer. Clinical Interventions in Aging. 10. 1155–1155. 16 indexed citations

Gravis, Gwénaëlle, Jean‐Marie Boher, Florence Joly, et al.. (2015). Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.. Journal of Clinical Oncology. 33(7_suppl). 140–140. 27 indexed citations

10.

Gravis, Gwénaëlle, Jean‐Marie Boher, Florence Joly, et al.. (2015). Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European Urology. 70(2). 256–262. 315 indexed citations breakdown →

11.

Bougnoux, Philippe, Jacques Bonneterre, P Soulié, et al.. (2015). Abstract P3-13-08: Modification of the response to chemotherapy of HER2 negative metastatic breast cancer by lipids of marine origin: A controlled, randomized, double blind dietary supplementation trial. Cancer Research. 75(9_Supplement). P3–13. 1 indexed citations

12.

Delbaldo, Catherine, D. Serin, M Mousseau, et al.. (2013). A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000). European Journal of Cancer. 50(1). 23–30. 7 indexed citations

13.

Oudard, Stéphane, Florence Gillaizeau, Séverine Peyrard, et al.. (2013). Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status.. Journal of Clinical Oncology. 31(15_suppl). e16009–e16009. 1 indexed citations

14.

Gross‐Goupil, Marine, A. Fourcade, Emmanuel Blot, et al.. (2012). Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. European Journal of Cancer. 48(5). 721–727. 33 indexed citations

15.

Hurvitz, Sara A., John Crown, John Forbes, et al.. (2009). CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).. Cancer Research. 69(24_Supplement). 47–47. 5 indexed citations

16.

Priou, Franck, Alain Zannetti, Alain Ravaud, et al.. (2007). Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Annals of Oncology. 18(6). 1064–1070. 42 indexed citations

17.

Oudard, Stéphane, Eugéniu Banu, Annick Vieillefond, et al.. (2007). Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) Study. The Journal of Urology. 177(5). 1698–1702. 134 indexed citations

18.

Piedbois, Pascal, D. Serin, Franck Priou, et al.. (2006). Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology. 18(1). 52–57. 30 indexed citations

19.

Piedbois, Pascal, D. Serin, Franck Priou, et al.. (2005). AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer. Journal of Clinical Oncology. 23(16_suppl). 647–647. 2 indexed citations

20.

Constans, J., et al.. (1993). [Arterial thrombosis of the arm and hemorrhagic rectocolitis. Report of a case].. PubMed. 18(2). 144–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact